Indaptus Therapeutics Appoints Experienced Independent Director David Natan to Board and Audit Committee

summarizeSummary

Indaptus Therapeutics has appointed David Natan, an experienced financial executive and CPA, as an independent director to its Board and Audit Committee, a move initiated by a significant investor.

check_boxKey Events

• Board Expansion and New Director Appointment

  The Board of Directors expanded from eight to nine members and appointed David Natan as a Class II director, effective January 8, 2026.

• Independent Director with Strong Financial Background

  Mr. Natan is an experienced financial executive and inactive CPA, having served as CEO of ForceField Energy and EVP/CFO of Pharma Net Development Group, and currently serves on other public company boards and audit committees.

• Appointment to Audit Committee

  Mr. Natan was appointed as a member of the Audit Committee, replacing Mr. Avraham Ben-Tzvi, who will remain a director and become a paid consultant. The Board determined Mr. Natan is an independent director.

• Nominee of Significant Investor

  Mr. Natan was designated by Mr. David E. Lazar, exercising his right to recommend directors under a December 22, 2025, securities purchase agreement, indicating active investor oversight.

auto_awesomeAnalysis

The appointment of David Natan as an independent director, particularly to the Audit Committee, is a positive development for Indaptus Therapeutics. Mr. Natan brings extensive financial and executive experience, including prior CFO and CEO roles, which will strengthen the company's governance and financial oversight. His nomination by a significant investor, David E. Lazar, suggests increased investor engagement and a commitment to robust board composition. This change is particularly beneficial for a micro-cap company like Indaptus, as strong, independent leadership is critical for navigating growth and ensuring accountability.